Benitec Limited (BLT.AX) Hepatitis B RNAi Program With Biomics Biotechnologies Moves To The Next Stage Following Successful Stage 1 Results  
2/23/2011 10:36:46 AM

Melbourne, Feb 22, 2011 (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, is pleased to announce that following the success of the first stage of its anti-viral program to develop an RNA interference (RNAi)-based therapy against Hepatitis B virus (HBV), conducted in collaboration with China-based Biomics Biotechnologies Co. Ltd, the companies have reached agreement to proceed to the next stage which is designed to develop an RNAi therapeutic to the point of pre-clinical studies in vivo.